Passive Immunization for the Treatment of HIV Infection

Mount Sinai Journal of Medicine

Volumn 65, Issue 1, 1998, Pages 22-26

  Jacobson, Jeffrey M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Acquired immunodeficiency syndrome; HIV; HIV antibodies; Immunization; Passive

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY;

AIDS RELATED COMPLEX; CD4 LYMPHOCYTE COUNT; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PASSIVE IMMUNIZATION; REVIEW;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBODIES, MONOCLONAL; CD4 LYMPHOCYTE COUNT; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNIZATION, PASSIVE;

EID: 0031607096     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Albert J, Abrahamsson B, Nagy K, et al. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990; 4:107-112.
2. Weiss RA, Clapham PR, Cheingsons-Popov R, et al. Neutralization of human T lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature 1985; 316: 69-72.
3. Guroff M, Brown M, Gallo RC. HTLV-III neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature 1985; 316:72-74.
4. Weber JN, Clapham PR, Weiss RA, et al. Human immunodeficiency virus infection in two cohorts of homosexual men: neutralizing sera and association of anti-GAG antibody with prognosis. Lancet 1987; 1:119-121.
5. Tyler DS, Lyerly HK, Weinhold KJ. Anti-HIV-1 ADCC. AIDS Res Hum Retroviruses 1989; 5:557-563.
6. Bonavida B, Katz J, Gottlieb M. Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. I. Defective trigger on NK cells for NKCF production by target cells, and partial restoration by IL2. J Immunol 1986; 137:1157-1163.
7. Hoffenbach A, Langladel-Demoyen P, Dadaglio G, et al. Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. J Immunol 1989; 142:452-462.
8. Prince AM, Reesink H, Pascual D, et al. Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res Hum Retroviruses 0000; 7:971-973.
9. Emini EA, Nara PL, Schleif WA, et al. Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J Virol 1990; 64:3674-3678.
10. sm infection by passive immunization in cynomolgus monkeys. Nature 1991; 352: 436-438.
11. Andrus L, McCarthy M, McCormack P, et al. Passive immunization against HIV-1 infection in HV-PBL-SCID mice [abstract]. In: Program Book: Conference on Advances in AIDS Vaccine Development (Alexandria, VA). Bethesda, MD: NIAID; 1993.
12. Safrit JT, Fung MSC, Andrews CA, et al. hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120. AIDS 1993; 7:15-21.
13. Cummins LM, Weinhold KJ, Mathews TJ, et al. Preparation and characterization of an intravenous solution of 1gG from human immunodeficiency virus-seropositive donors. Blood 1991; 77:1111-1117.
14. D'Souza MP, Geyer SJ, Hanson CV, et al. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration. AIDS 1994; 8:169-181.
15. D'Souza MP, Milman G, Bradac JA, et al. Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies. AIDS 1995; 9:867-874.
16. Ojo-Amaize EA, Nishanian P, Keith DE, et al. Antibodies to human immunodeficiency virus in human sera induced cell-mediated lysis of human immunodeficiency virus-infected cells. J Immunol 1987; 139:2458-2468.
17. Gregersen JP, Mehdi S, Baur A, Hilfenhaus J. Antibody- and complement mediated lysis of HIV-infected cells and inhibition of viral replication. J Med Virol 1990; 30:287-293.
18. Spear GT, Sullivan BL, Landay AL, Lint TF. Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis. J Virol 1990; 64:5869-5873.
19. Fung MSC, Sun C, Sun NC, et al. Monoclonal antibodies that neutralize HIV-1 virions and inhibit syncytium formation by infected cells. BioTechnology 1987; 5:940-946.
20. Lyerly HK, Matthews TJ, Langlois AJ, et al. Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determines on normal lymphocytes and expressed by infected cells serves as target for immune attack. Proc Natl Acad Sci USA 1987; 84:4601-4605.
21. Siliciano RF, Lawton T, Knoll C, et al. Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: effects of HIV sequence variation and a mechanism for CD4+ cell depletion. Cell 1988; 54:561-575.
22. Orientas RJ, Hildreth JEK, Obah E, et al. Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine. Science 1990; 248: 1234-1237.
23. Liegler TJ, Stites DP. HIV-1gp120 and anti-gp120 induce reversible unresponsiveness in peripheral CD4 T lymphocytes. J Acquir Immune Defic Syndr 1994; 7:340-348.
24. Theodore AC, Kornfeld H, Wallace RP, Criukshank WW. CD4 modulation of noninfected human T lymphocytes by HIV-1 envelope glycoprotein gp120: contributions to the immunosuppression seen in HFV-1 infection by induction of CD4 and CD4 unresponsiveness. J Acquir Immune Defic Syndr 1994; 7:899-907.
25. Takeda A, Tuazon CV, Ennis FA. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 1988; 86:8055-8058.
26. Robinson WE, Montefiore DC, Gillespie DH, Mitchell WM. Complement mediated, antibody dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA synthesis and infectious virus release. J Acquir Immune Defic Syndr 1989; 2: 33-42.
27. Jackson GG, Perkins JT, Rubenis M, et al. Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS. Lancet 1988; 2:647-654.
28. Karpas A, Hill F, Youle M, et al. Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome. Proc Natl Acad Sci USA 1988; 85: 9234-9237.
29. Busch MP, Henrard DR, Hewlett IK, et al. Poor sensitivity, specificity, and reproducibility of detection of HIV-1 DNA in serum by polymerase chain reaction. The Transfusion Safety Study Group. J Acquir Immune Defic Syndr 1992; 5:872-877.
30. Jacobson JM, Colman N, Ostrow NA, et al. Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection. J Infect Dis 1993; 168: 298-305.
31. Karpas A, Gillson W, Bevan PC, Oates JD. Lytic infection by Britisch AIDS virus and development of rapid cell tests for antiviral antibodies. Lancet 1985; 2:695-697.
32. Colman N, Danon AD, Jacobson JM, Prince AM. Laboratory assays for HIV: lack of concordance between HIV neutralizing antibody and immunoperoxidase titers [abstract]. In: Programs and abstracts: VI International Conference on AIDS (San Francisco). San Francisco: University of California; 1990. p. 522.
33. Vittecog D, Mattlinger B, Barre-Sinoussi F, et al. Passive immunotherapy in AIDS: a randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusions of seronegative plasma. J Infect Dis 1992; 165:364-368.
34. Vittecog D, Chevret S, Morand-Joubert L, et al. Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in antihuman immunodeficiency virus 1 antibodies vs transfusions of seronegative plasma. Proc Natl Acad Sci USA 1995; 92:1194-1199.
35. Levy J, Youvan T, Lee ML, et al. Passive hyperimmune plasma therapy in the treatment of acquired immunodeficiency syndrome: results of a 12 month multicenter double-blind controlled trial. Blood 1994; 84:2130-2135.
36. Lefrere JJ, Morand-Joubert L, Mariotti M. Passive immunotherapy in AIDS: biological results of a double-blind randomized study [abstract]. In: Program and abstracts: 2nd National Conference Human Retroviruses and Related Infections (Washington, D.C.). Washington, D.C.: American Society for Microbiology; 1995. LB10.
37. Osther K, Wiik A, Black F, et al. PASSHIV-1 treatment of patients with HIV-1 infection. A preliminary report of a phase 1 trial of hyperimmune porcine immunoglobulin to HIV-1. AIDS 1992; 6:1457-1464.
38. Hinkula J, Bratt G, Gilljam G, et al. Immunological and virological interactions in patients receiving passive immunotherapy with HIV-1 neutralizing monoclonal antibodies. J Acquir Immune Defic Syndr 1994; 7:940-951.
39. Gunthard HF, Gowland PL, Schupback J. A phase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V# loop of human immunodeficiency virus type 1 gp120. J Infect Dis 1994; 170:1384-1393.